A valsartan levoamlodipine tablet composition, valsartan levoamlodipine tablet and its preparation process and application
Through the dry granulation method of valsartan and sodium carboxymethyl starch coating treatment, the problem of poor release of lemulodipine in valsartan lemulodipine tablets was solved, and efficient drug release and bioavailability were achieved promote.
Patent Information
- Application Number
- CN202411232675.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-04
AI Technical Summary
The prior art is difficult to provide a valsartan lemudipine tablet that is equivalent to lemudipine benzenesulfonate and valsartan and its preparation process, resulting in poor release effect of valsartan and lemudipine. .
Valsartan is made by dry granulation method alone, combined with mixed coating of lemudipine benzenesulfonate and sodium carboxymethyl starch, and isolate valsartan by sodium carboxymethyl starch. Contact with levamlodipine benzenesulfonate, thereby accelerating the in vitro release of levamlodipine.
The release rate of valsartan lemudipine tablets in acetic acid buffer with pH 4.5 exceeded 85% within 15 minutes, and the F2 value of valsartan is greater than 50, which significantly improved bioavailability and clinical Security.
Smart Images

Figure CN118717696B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations and relates to a valsartan levoamlodipine tablet composition, a valsartan levoamlodipine tablet and a preparation process and application thereof. Background Art
[0002] Valsartan is an angiotensin II receptor antagonist antihypertensive drug. It blocks the type I (AT1) receptor of angiotensin II, increases the plasma level of angiotensin II, stimulates the unblocked AT2 receptor and counteracts the AT1 receptor, thereby achieving the effect of dilating blood vessels and lowering blood pressure. Amlodipine besylate is indicated for hypertension and can be used alone or in combination with other antihypertensive drugs. It is suitable for the symptomatic treatment of chronic stable angina pectoris.
[0003] Valsartan amlodipine tablets are used to treat hypertension, especially for patients whose blood pressure cannot be adequately controlled by monotherapy. In valsartan amlodipine tablets, amlodipine besylate belongs to the class of calcium channel antagonists. Amlodipine is a racemic body that can be split into levoamlodipine and dexamlodipine, and the toxicity of levoamlodipine is lower than that of dexamlodipine. Therefore, it is very necessary to develop a valsartan levoamlodipine tablet.
[0004] Chinese patent CN113712927A discloses a compound valsartan levamlodipine tablet and a preparation method thereof. The compound valsartan levamlodipine tablet has a formula as follows (1) or (2): (1) 160 parts of valsartan, 3.47 parts of levamlodipine besylate, 80-120 parts of diluent, 30-50 parts of disintegrant, 2-4 parts of glidant, 8-12 parts of lubricant, and 20-40 parts of coating agent; (2) 80 parts of valsartan, 3.47 parts of levamlodipine besylate, 40-60 parts of diluent, 10-30 parts of disintegrant, 1-3 parts of glidant, 3-5 parts of lubricant, and 5-15 parts of coating agent; the diluent is one or two of microcrystalline cellulose, lactose, and calcium hydrogen phosphate, and the water content is 0.1-1.0%. This technology uses a dry granulation process. Since valsartan has a high viscosity and is sticky when it comes into contact with water, the dry granulation process avoids the need to add a wetting agent during granulation, is easy to operate in large-scale production, reduces production time, and improves production efficiency. In addition, this method adds a desiccant to the package to improve product stability. However, this method is to dry granulate levamlodipine besylate and valsartan at the same time, and valsartan seriously affects the release effect of levamlodipine besylate.
[0005] Chinese patent CN114917225A discloses a preparation method and preparation device of a valsartan-levamlodipine composition, including the following preparation steps: preparing materials: the materials include valsartan, levamlodipine besylate, fillers, disintegrants, lubricants, retention aids and adhesives; wherein the fillers include microcrystalline cellulose and dextrin; the adhesives include starch and sodium carboxymethyl cellulose; by combining valsartan and levamlodipine besylate, the dosage of the drug is precisely controlled, the efficacy of the composition is improved, and the risk of some elderly patients taking less or missing drugs is reduced. However, this method also co-granulates valsartan and levamlodipine, and valsartan seriously affects the release effect of levamlodipine besylate.
[0006] Chinese patent CN114917226A discloses a valsartan levamlodipine composition, comprising valsartan 815g, levamlodipine besylate 70g, filler, disintegrant, lubricant, retention aid, sustained-release agent, wherein the sustained-release agent is carboxypropyl methylcellulose and carbomer, 645g in total. Valsartan and levamlodipine besylate two kinds of drug combination therapy reduce the risk of some elderly patients due to less or missed medication. However, the method wet granulates levamlodipine besylate with valsartan, and valsartan has a serious impact on the release effect of levamlodipine besylate.
[0007] The inventor has studied existing drugs such as valsartan amlodipine tablets, valsartan tablets (capsules), levamlodipine besylate tablets, and amlodipine besylate tablets and found that both unilateral levamlodipine besylate tablets and unilateral amlodipine besylate tablets are rapidly dissolved. However, as long as valsartan is in contact with amlodipine besylate or levamlodipine besylate, the in vitro release of levamlodipine will be delayed. Therefore, in order to enable the mixture of valsartan and levamlodipine to achieve the same rapid release effect as amlodipine besylate tablets or levamlodipine besylate tablets, it is necessary to provide a new valsartan levamlodipine preparation and its preparation process.
[0008] In summary, it is difficult in the prior art to provide a valsartan levoamlodipine tablet having an equivalent release to levoamlodipine besylate and valsartan and a preparation process thereof. Summary of the invention
[0009] In view of this, in view of the above-mentioned problems in the prior art, the purpose of the present invention is to provide a valsartan levamlodipine tablet composition, a valsartan levamlodipine tablet and a preparation process and application thereof, which can simultaneously achieve an F2 value greater than 50 compared with a single valsartan tablet and an in vitro simulated cumulative release rate of levamlodipine of more than 85% in 15 min.
[0010] The inventor unexpectedly discovered that by using a method of dry granulating valsartan alone and coating levamlodipine besylate with sodium carboxymethyl starch, the sodium carboxymethyl starch is coated on levamlodipine besylate, thereby isolating valsartan and levamlodipine besylate from contacting over a large area, thereby accelerating the in vitro release of levamlodipine. This effect cannot be achieved by using disintegrants such as cross-linked polyvinylpyrrolidone and cross-linked sodium carboxymethyl cellulose.
[0011] To achieve the above-mentioned object of the invention, on the one hand, the present invention provides a valsartan levamlodipine tablet composition, which is composed of a valsartan composition and a levamlodipine besylate composition;
[0012] The valsartan composition is composed of valsartan, a filler, a disintegrant, a glidant and a lubricant 1;
[0013] The levoamlodipine besylate composition is composed of levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2;
[0014] The particle size d90 of the valsartan is 10-100 μm, and the particle size d90 of the levamlodipine besylate is 20-90 μm;
[0015] In the levoamlodipine besylate composition, the mass ratio of the levoamlodipine besylate to the sodium carboxymethyl starch is 7:9-14;
[0016] The lubricant 1 is selected from at least one of magnesium stearate and calcium stearate;
[0017] The lubricant 2 is selected from at least one of magnesium stearate and calcium stearate.
[0018] The term "particle size d90" refers to the particle size when the cumulative particle distribution reaches 90%, that is, 90% of the particles have a particle size smaller than the value of particle size d90, and 10% of the particles have a particle size greater than or equal to the value of particle size d90.
[0019] Preferably, the particle size d90 of the valsartan is 11.8-98.2 μm.
[0020] As an example of the present invention, the particle size d90 of the valsartan is selected from 11.8 μm, 40.3 μm, 50.4 μm, 55.4 μm, 60.5 μm or 98.2 μm.
[0021] As the best example of the present invention, the particle size d90 of the valsartan is 11.8 μm.
[0022] Preferably, the particle size d90 of the levamlodipine besylate is 21.3-89.5 μm.
[0023] As an example of the present invention, the particle size d90 of the levamlodipine besylate is selected from 21.3 μm, 62.2 μm, 62.3 μm, 62.4 μm, 64.4 μm or 89.5 μm.
[0024] As the best example of the present invention, the particle size d90 of the levamlodipine besylate is 89.5 μm.
[0025] As an example of the present invention, the mass ratio of the levamlodipine besylate to the sodium carboxymethyl starch is selected from 1:2 (ie, 7:14), 7:10, 7:9, 7:10.1 or 7:13.
[0026] As the best example of the present invention, the mass ratio of the levamlodipine besylate to the sodium carboxymethyl starch is 1:2 (ie 7:14).
[0027] Preferably, in the valsartan composition, the filler is selected from at least one of microcrystalline cellulose and pregelatinized starch, the disintegrant is selected from at least one of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone, the glidant is colloidal silicon dioxide, and the lubricant 1 is magnesium stearate.
[0028] More preferably, in the valsartan composition, the disintegrant is selected from sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone.
[0029] More preferably, and as an example of the present invention, the microcrystalline cellulose is microcrystalline cellulose 102.
[0030] More preferably, and as an example of the present invention, in the disintegrant, the sodium carboxymethyl starch is sodium carboxymethyl starch Primojel.
[0031] More preferably, and as an example of the present invention, the crospovidone is crospovidone XL.
[0032] As an example of the present invention, in the valsartan composition, the filler is microcrystalline cellulose 102.
[0033] As an example of the present invention, in the valsartan composition, the filler is microcrystalline cellulose 102 and pregelatinized starch.
[0034] Preferably, in the levamlodipine besylate composition, the lubricant 2 is magnesium stearate.
[0035] Preferably, in the valsartan composition, the mass ratio of the valsartan, the filler, the disintegrant, the glidant and the lubricant 1 is 80:50-75:8-22:1.3-3:0.5-3.
[0036] Preferably, in the levoamlodipine besylate composition, the mass ratio of the levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 is 7:9-14:1-2.4.
[0037] More preferably, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:55-65:20-22:1.3:3:3.5:5-7:1.2.
[0038] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:55:22:1.3:3:3.5:7:1.2.
[0039] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch, lubricant 2 in the levoamlodipine besylate composition is 80:65:20:1.3:3:3.5:5:1.2.
[0040] More preferably, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:50-75:8-15:3:0.5:7:9-14:1-1.5.
[0041] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:57:15:3:0.5:7:10.1:1.5.
[0042] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:75:11:3:0.5:7:9:1.5.
[0043] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:62:8:3:0.5:7:13:1.5.
[0044] As an example of the present invention, the mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1 in the valsartan composition and levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 in the levoamlodipine besylate composition is 80:50:10:3:0.5:7:14:1.
[0045] As the most preferred embodiment of the present invention, in the valsartan levamlodipine tablet composition, the filler is microcrystalline cellulose 102, the disintegrant is cross-linked polyvinylpyrrolidone XL, the glidant is colloidal silicon dioxide, the lubricant 1 is magnesium stearate, and the lubricant 2 is magnesium stearate;
[0046] The mass ratio of valsartan, filler, disintegrant, flow agent, lubricant 1, levamlodipine besylate, sodium carboxymethyl starch and lubricant 2 is 80:55:22:1.3:3:3.5:7:1.2;
[0047] The particle size d90 of the valsartan is 11.8 μm, and the particle size d90 of the levamlodipine besylate is 89.5 μm.
[0048] Preferably, in the valsartan composition, the mass percentage of valsartan in the valsartan levoamlodipine tablet composition is 42.78%-48.34%, the mass percentage of the filler in the valsartan levoamlodipine tablet composition is 30.21%-40.11%, the mass percentage of the disintegrant in the valsartan levoamlodipine tablet composition is 4.57%-12.72%, the mass percentage of the glidant in the valsartan levoamlodipine tablet composition is 0.73%-1.81%, and the mass percentage of the lubricant 1 in the valsartan levoamlodipine tablet composition is 0.27%-1.73%.
[0049] More preferably, in the valsartan composition, the mass percentage of valsartan in the valsartan levoamlodipine tablet composition is 46.24%, the mass percentage of the filler in the valsartan levoamlodipine tablet composition is 31.79%, the mass percentage of the disintegrant in the valsartan levoamlodipine tablet composition is 12.72%, the mass percentage of the valsartan levoamlodipine tablet composition is 0.75%, and the mass percentage of the lubricant 1 in the valsartan levoamlodipine tablet composition is 1.73%.
[0050] Preferably, in the levamlodipine besylate composition, the mass percentage of levamlodipine besylate in the valsartan levamlodipine tablet composition is 1.96%-4.23%, the mass percentage of sodium carboxymethyl starch in the valsartan levamlodipine tablet composition is 2.79%-8.46%, and the mass percentage of lubricant 2 in the valsartan levamlodipine tablet composition is 0.60%-0.86%.
[0051] More preferably, in the levoamlodipine besylate composition, the mass percentage of the levoamlodipine besylate in the valsartan levoamlodipine tablet composition is 2.02%, the mass percentage of the sodium carboxymethyl starch in the valsartan levoamlodipine tablet composition is 4.05%, and the mass percentage of the lubricant 2 in the valsartan levoamlodipine tablet composition is 0.69%.
[0052] On the other hand, the present invention provides a valsartan levoamlodipine tablet, comprising a tablet core and a coating layer, wherein the tablet core is made of the above-mentioned valsartan levoamlodipine tablet composition.
[0053] In the valsartan levamlodipine tablets, preferably, the mass of the coating layer is 2.5%-5.5%, more preferably 4.5% of the mass of the tablet core; and the coating layer is prepared from a gastric-soluble film coating premix.
[0054] In the valsartan amlodipine tablets, more preferably, the coating layer is prepared from a gastric soluble film coating premix aqueous suspension with a mass concentration of 10%-15%.
[0055] In another aspect, the present invention provides a preparation process of the above-mentioned valsartan levamlodipine tablets, comprising the following steps:
[0056] S1, mixing the prescribed amount of the valsartan composition, and dry granulating to obtain valsartan granules;
[0057] S2, mixing the sodium carboxymethyl starch and levoamlodipine besylate in the prescription amount of the levoamlodipine besylate composition for 1-5 min, 45%-55% of the mass of the valsartan granules obtained in step S1, mixing for 8-10 min, and then adding the remaining mass of the valsartan granules obtained in step S1, mixing for 8-10 min, to obtain coated granules;
[0058] S3, mixing the coated particles obtained in step S2 with the lubricant 2 in the prescribed amount of the levamlodipine besylate composition, and tableting to obtain tablet cores;
[0059] S4, coating the tablet cores obtained in step S3 to obtain valsartan levamlodipine tablets.
[0060] Preferably, in step S1, the dry granulation is specifically performed using a dry granulator, with a feed speed of 25-80 rpm, a roller speed of 5-20 rpm, an oil pump pressure of 30-70 bar, a roller gap of 0.4-1.0 mm, a crushing speed of 80-100 rpm, a granulation speed of 80-100 rpm, and a granulation screen aperture of 0.8 mm.
[0061] More preferably, the feed speed is 45 rpm.
[0062] More preferably, the rotation speed of the pressing roller is 15 rpm.
[0063] More preferably, the oil pump pressure is 50 bar.
[0064] More preferably, the gap between the pressing rollers is 0.7 mm.
[0065] More preferably, the pulverizing rotation speed is 95 rpm.
[0066] Preferably, in step S2:
[0067] The sodium carboxymethyl starch and levoamlodipine besylate in the prescribed amount of the levoamlodipine besylate composition were mixed for 3 minutes.
[0068] Preferably, in step S2: 50% of the mass of the valsartan granules obtained in step S1 is added, mixed for 8-10 minutes, and then the remaining mass of the valsartan granules obtained in step S1 is added, mixed for 8-10 minutes to obtain coated granules.
[0069] More preferably, in step S2: 50% of the mass of the valsartan granules obtained in step S1 is added, mixed for 10 minutes, and then the remaining mass of the valsartan granules obtained in step S1 is added, mixed for 8 minutes to obtain coated granules.
[0070] Preferably, the mixing time in step S3 is 3-7 min, more preferably 3 min.
[0071] Preferably, in step S3, the average hardness of the tablet is 50-90N, more preferably 85N.
[0072] Preferably, in step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a suspension aqueous solution with a mass concentration of 10%-15%, so that the mass of the coating accounts for 2.5%-5.5% of the mass of the tablet core obtained in step S3.
[0073] More preferably, and as an example of the present invention, in step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a suspension aqueous solution with a mass concentration of 10%.
[0074] More preferably, and as an example of the present invention, in step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a suspension aqueous solution with a mass concentration of 15%.
[0075] More preferably, and as an example of the present invention, in step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a 15% mass concentration suspension aqueous solution for coating, so that the coating mass accounts for 4.5% of the mass of the tablet core obtained in step S3.
[0076] In another aspect, the present invention provides application of the above preparation process in drug production.
[0077] The preparations used for human bioequivalence comparison with the valsartan levamlodipine tablets provided by the present invention are amlodipine besylate tablets and valsartan tablets. Amlodipine besylate tablets dissolve quickly, and the dosage of levamlodipine is reduced compared with amlodipine to achieve the same effect, which can significantly improve bioavailability.
[0078] The beneficial effects of the present invention are:
[0079] (1) The production process provided by the present invention is simple and suitable for large-scale production.
[0080] (2) In vitro dissolution experiments showed that the valsartan levamlodipine tablets prepared by the present invention had a levamlodipine release rate of more than 85% within 15 min in an acetate buffer solution at pH 4.5, and the F2 value of valsartan was greater than 50.
[0081] (3) After the coating treatment of levamlodipine besylate, the in vitro and control preparations can achieve in vitro similarity, which is of great significance in terms of clinical effectiveness and bioavailability; the invention is a compound preparation, and the dosage of levamlodipine besylate is reduced compared with single amlodipine, the clinical toxicity is reduced, the clinical safety is greatly improved, and the patient compliance is relatively improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The invention discloses a process flow chart of the preparation of valsartan levamlodipine tablets.
[0083] Figure 2 It is a dissolution curve of levoamlodipine besylate in the valsartan levoamlodipine tablets provided in the control preparation and Examples 1 to 6 in an acetate buffer solution at pH 4.5.
[0084] Figure 3 It is a dissolution curve of levoamlodipine besylate in valsartan levoamlodipine tablets provided by the control preparation and comparative examples 1 to 7 in acetate buffer at pH 4.5.
[0085] Figure 4It is a dissolution curve of levoamlodipine besylate in valsartan levoamlodipine tablets provided by the control preparation and comparative examples 9 to 14 in acetate buffer at pH 4.5.
[0086] Figure 5 It is a dissolution curve of levoamlodipine besylate in valsartan levoamlodipine tablets provided by the control preparation and comparative examples 15 to 21 in acetate buffer at pH 4.5.
[0087] Figure 6 It is a dissolution curve of valsartan in the valsartan-levoamlodipine tablets provided in the control preparation and Examples 1 to 6 in acetate buffer at pH 4.5.
[0088] Figure 7 It is a dissolution curve of valsartan in the valsartan-levoamlodipine tablets provided by the control preparation and comparative examples 18 to 21 in acetate buffer at pH 4.5. DETAILED DESCRIPTION
[0089] Terms and Claims of the Present Invention:
[0090] 1. The articles “a”, “an” and “the” include plural referents unless expressly limited to one or more referents otherwise.
[0091] 2. Numerical range: Unless otherwise expressly stated, all ranges or ratios disclosed herein will be understood to include any and all sub-ranges or sub-ratios contained therein. For example, a range or ratio of 1 to 30 stated should be considered to be included between a minimum value of 1 and a maximum value of 30, and any sub-range or sub-ratio, integer, decimal, or sub-range or sub-ratio consisting of integers or decimals including the end points.
[0092] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.
[0093] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0094] In the following examples, the sources of some reagents are shown in Table 1.
[0095] Table 1:
[0096]
[0097] The process flow of the valsartan levamlodipine tablets provided by the present invention is shown in Figure 1 .
[0098] The in vitro evaluation method of valsartan levoamlodipine tablets provided by the present invention is as follows: the general dissolution method 2 of the 2020 edition of the "Chinese Pharmacopoeia", the paddle method, the medium pH 4.5 acetate buffer, the volume 900 mL, the rotation speed: 50 rpm; the detection method: the high performance liquid chromatography method, the wavelength: 237 nm, the chromatographic column: C18 (3.9 mm × 150 mm, 5 μm), when the dissolution test is carried out by using the dissolution instrument, 1 tablet / cup of the homemade valsartan levoamlodipine tablet is put into, and 1 tablet of the valsartan tablet control and the levoamlodipine besylate tablet control are put into each cup at the same time, and after starting the dissolution instrument, samples are taken for inspection at each time point.
[0099] The preparation method of pH 4.5 acetate buffer solution refers to the preparation method provided in the Chinese Pharmacopoeia. Specifically, 18 g of sodium acetate trihydrate and 9.8 mL of glacial acetic acid are mixed with an appropriate amount of water to fully dissolve, and the volume is adjusted to 1000 mL.
[0100] The control preparations provided by the present invention are valsartan tablets (specification: 80 mg, batch number: AR7108E, manufacturer: NOVARTISPHARMACEUTICALS CORP) and amlodipine besylate tablets (specification: 5 mg, batch number: 8150610, manufacturer: Pfizer Pharmaceuticals Co., Ltd.).
[0101] Example 1
[0102] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 2.
[0103] Table 2:
[0104]
[0105] The preparation method of valsartan levamlodipine tablets in Example 1 is as follows:
[0106] (1) Weigh the prescribed amount of valsartan, crospovidone XL, microcrystalline cellulose 102, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate the particles. Set the feed speed to 45 rpm, the roller speed to 15 rpm, the oil pump pressure to 50 bar, the roller gap to 0.7 mm, the crushing speed to 95 rpm, the granulation speed to 95 rpm, and the granulation screen aperture to 0.8 mm to obtain valsartan granules.
[0107] (2) Levoamlodipine besylate coating treatment: mix the prescribed amount of sodium carboxymethyl starch and levoamlodipine besylate for 3 minutes, add 50% of the mass of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes to form coated granules;
[0108] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 3 minutes;
[0109] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 85N;
[0110] (5) Coating: A gastric-soluble film coating premix is prepared into a 10% mass concentration aqueous suspension for coating. The mass of the coating layer is expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer is 4.5% of the mass of the tablet core.
[0111] Example 2
[0112] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 3.
[0113] Table 3:
[0114]
[0115] The preparation method of valsartan levamlodipine tablets in Example 2 is as follows:
[0116] (1) Weigh the prescribed amount of valsartan, crospovidone XL, microcrystalline cellulose 102, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate them. Set the feed speed to 80 rpm, the roller speed to 6 rpm, the oil pump pressure to 35 bar, the roller gap to 1.0 mm, the crushing speed to 80 rpm, the granulation speed to 80 rpm, and the granulation screen mesh size to 0.8 mm to obtain valsartan granules;
[0117] (2) Levoamlodipine besylate coating treatment: mix the prescribed amount of sodium carboxymethyl starch and levoamlodipine besylate for 3 minutes, add 50% of the mass of the valsartan granules obtained in (1) and mix for 8 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 10 minutes to form coated granules;
[0118] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 7 minutes;
[0119] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 55N;
[0120] (5) Coating: A gastric-soluble film coating premix is prepared into a 15% mass concentration aqueous suspension for coating. The mass of the coating layer is expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer is 3.5% of the mass of the tablet core.
[0121] Example 3
[0122] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 4.
[0123] Table 4:
[0124]
[0125] The preparation method of valsartan levamlodipine tablets in Example 3 is as follows:
[0126] (1) Weigh the prescribed amount of valsartan, sodium carboxymethyl starch (disintegrant), microcrystalline cellulose 102, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate the particles. Set the feed speed to 80 rpm, the roller speed to 6 rpm, the oil pump pressure to 35 bar, the roller gap to 0.4 mm, the crushing speed to 95 rpm, the granulation speed to 80 rpm, and the granulation screen aperture to 0.8 mm to obtain valsartan granules.
[0127] (2) Levoamlodipine besylate coating treatment: the prescribed amount of sodium carboxymethyl starch (coating) and levamlodipine besylate were mixed for 3 minutes, 50% of the mass of the valsartan granules obtained in (1) were added and mixed for 8 minutes, and then the remaining mass of the valsartan granules obtained in (1) were added and mixed for 10 minutes to form coated granules;
[0128] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 3 minutes;
[0129] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 55N;
[0130] (5) Coating: A gastric-soluble film coating premix is prepared into a 12% mass concentration aqueous suspension for coating. The mass of the coating layer is expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer is 4.5% of the mass of the tablet core.
[0131] Example 4
[0132] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 5.
[0133] Table 5:
[0134]
[0135] The preparation method of valsartan levamlodipine tablets in Example 4 is as follows:
[0136] (1) Weigh the prescribed amount of valsartan, crosslinked sodium carboxymethyl cellulose, microcrystalline cellulose 102, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate them. Set the feed speed to 25 rpm, the roller speed to 20 rpm, the oil pump pressure to 35 bar, the roller gap to 0.6 mm, the crushing speed to 80 rpm, the granulation speed to 100 rpm, and the granulation screen mesh size to 0.8 mm to obtain valsartan granules;
[0137] (2) Levoamlodipine besylate coating treatment: mix the prescribed amount of sodium carboxymethyl starch and levoamlodipine besylate for 3 minutes, add 50% of the mass of the valsartan granules obtained in (1) and mix for 8 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 10 minutes to form coated granules;
[0138] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 7 minutes;
[0139] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 90N;
[0140] (5) Coating: A gastric-soluble film coating premix is prepared into a 10% mass concentration aqueous suspension for coating. The mass of the coating layer is expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer is 4.5% of the mass of the tablet core.
[0141] Example 5
[0142] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 6.
[0143] Table 6:
[0144]
[0145] The preparation method of valsartan levamlodipine tablets in Example 5 is as follows:
[0146] (1) Weigh the prescribed amount of valsartan, sodium carboxymethyl starch (disintegrant), pregelatinized starch, microcrystalline cellulose 102, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate the particles. Set the feed speed to 25 rpm, the roller speed to 20 rpm, the oil pump pressure to 35 bar, the roller gap to 0.6 mm, the crushing speed to 80 rpm, the granulation speed to 100 rpm, and the granulation screen mesh size to 0.8 mm to obtain valsartan granules.
[0147] (2) Levoamlodipine besylate coating treatment: the prescribed amount of sodium carboxymethyl starch (coating) and levamlodipine besylate were mixed for 5 minutes, 50% of the mass of the valsartan granules obtained in (1) were added and mixed for 8 minutes, and then the remaining mass of the valsartan granules obtained in (1) were added and mixed for 10 minutes to form coated granules;
[0148] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 7 minutes;
[0149] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 90N;
[0150] (5) Coating: A gastric-soluble film coating premix is prepared into a 10% mass concentration aqueous suspension for coating. The mass of the coating layer is expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer is 4.5% of the mass of the tablet core.
[0151] Example 6
[0152] Valsartan levamlodipine tablets. The ingredients and contents in the tablets are shown in Table 7.
[0153] Table 7:
[0154]
[0155] The preparation method of valsartan levamlodipine tablets in Example 6 is as follows:
[0156] (1) Weigh the prescribed amount of valsartan, sodium carboxymethyl starch (disintegrant), microcrystalline cellulose 102, colloidal silicon dioxide, and magnesium stearate (lubricant 1), mix them evenly, and use a dry granulator to granulate the particles. Set the feed speed to 35 rpm, roller speed to 20 rpm, oil pump pressure to 50 bar, roller gap to 0.9 mm, crushing speed to 80 rpm, granulation speed to 85 rpm, and granulation screen aperture to 0.8 mm to obtain valsartan granules.
[0157] (2) Levoamlodipine besylate coating treatment: the prescribed amount of sodium carboxymethyl starch (coating) and levamlodipine besylate were mixed for 1 minute, 50% of the mass of the valsartan granules obtained in (1) were added and mixed for 8 minutes, and then the remaining mass of the valsartan granules obtained in (1) were added and mixed for 10 minutes to form coated granules;
[0158] (3) Total mixing: Add the prescribed amount of magnesium stearate (lubricant 2) to the coated granules and mix for 7 minutes;
[0159] (4) Tableting: Tableting is performed according to the theoretical tablet weight, with an average hardness of 60N;
[0160] (5) Coating: A gastric-soluble film coating premix was prepared into a 10% mass concentration aqueous suspension for coating. The mass of the coating layer was expected to be 2.5%-5.5% of the mass of the tablet core, and the actual mass of the coating layer was 5.3% of the mass of the tablet core.
[0161] Comparative Example 1
[0162] Valsartan levoamlodipine tablets are prepared by the dry preparation method described in Example 1 of the patent publication with publication number CN115869274A.
[0163] Comparative Example 2
[0164] Compared with Example 1, the only difference is that step (2) is changed to "mix all the valsartan granules obtained in (1) with the prescribed amount of levamlodipine besylate and sodium carboxymethyl starch for a total of 21 minutes to form coated granules", and the rest are the same.
[0165] Comparative Example 3
[0166] Compared with Example 1, the only difference is that the mixing time of levamlodipine besylate and sodium carboxymethyl starch in (2) is changed from 3 min to 0.8 min, and the rest is the same.
[0167] Comparative Example 4
[0168] Compared with Example 1, the only difference is that the mixing time of levamlodipine besylate and sodium carboxymethyl starch in (2) is changed from 3 minutes to 6 minutes, and the rest is the same.
[0169] Comparative Example 5
[0170] Compared with Example 1, the only difference is that in step (2), the "add 50% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 40% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 8 minutes", and the rest are the same.
[0171] Comparative Example 6
[0172] Compared with Example 1, the only difference is that in step (2), the "add 50% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 60% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 8 minutes", and the rest are the same.
[0173] Comparative Example 7
[0174] Compared with Example 1, the only difference is that in step (2), the "add 50% of the mass of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 50% of the mass of the valsartan granules obtained in (1) and mix for 7 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes", and the rest are the same.
[0175] Comparative Example 8
[0176] Compared with Example 1, the only difference is that in step (2), the "add 50% of the mass of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 50% of the mass of the valsartan granules obtained in (1) and mix for 11 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes", and the rest are the same.
[0177] Comparative Example 9
[0178] Compared with Example 1, the only difference is that in step (2), the "add 50% of the mass of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 50% of the mass of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining mass of the valsartan granules obtained in (1) and mix for 7 minutes", and the rest are the same.
[0179] Comparative Example 10
[0180] Compared with Example 1, the only difference is that in step (2), the "add 50% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 8 minutes" is changed to "add 50% by weight of the valsartan granules obtained in (1) and mix for 10 minutes, then add the remaining weight of the valsartan granules obtained in (1) and mix for 11 minutes", and the rest are the same.
[0181] Comparative Example 11
[0182] Compared with Example 1, the only difference is that the sodium carboxymethyl starch in the formula and preparation method is replaced with cross-linked polyvinylpyrrolidone of the same mass, and the rest are the same.
[0183] Comparative Example 12
[0184] Compared with Example 1, the only difference is that the sodium carboxymethyl starch in the formula and preparation method is replaced with cross-linked sodium carboxymethyl cellulose of the same mass, and the rest is the same.
[0185] Comparative Example 13
[0186] Compared with Example 1, the only difference is that the sodium carboxymethyl starch in the formula and preparation method is replaced with low-substituted hydroxypropyl cellulose of the same mass, and the rest is the same.
[0187] Comparative Example 14
[0188] Compared with Example 1, the only difference is that the dosage of sodium carboxymethyl starch is adjusted to 2.8 mg / tablet, the mass percentage of each component in the tablet core and the total mass of the tablet core are changed accordingly, and the rest are the same.
[0189] Comparative Example 15
[0190] Compared with Example 1, the only difference is that the dosage of sodium carboxymethyl starch is adjusted to 17 mg / tablet, the mass percentage of each component in the tablet core and the total mass of the tablet core are changed accordingly, and the rest are the same.
[0191] Comparative Example 16
[0192] Compared with Example 1, the difference is that the dosage of sodium carboxymethyl starch is adjusted to 7.6 mg / tablet, at this time, the mass ratio of levamlodipine besylate and sodium carboxymethyl starch is about 1:2.17, the mass percentage of each component in the tablet core and the total mass of the tablet core change accordingly, and the other conditions are the same as in Example 1.
[0193] Comparative Example 17
[0194] Compared with Example 4, the difference is that the dosage of sodium carboxymethyl starch is adjusted to 8 mg / tablet, the mass percentage of each component in the tablet core and the total mass of the tablet core are changed accordingly, and the other conditions are the same as those in Example 4.
[0195] Comparative Example 18
[0196] Compared with Example 1, the only difference is that the particle size d90 of the valsartan raw material is changed to 8.8 μm, and the rest are the same.
[0197] Comparative Example 19
[0198] Compared with Example 1, the only difference is that the particle size d90 of the valsartan raw material is changed to 105.5 μm, and the rest are the same.
[0199] Comparative Example 20
[0200] Compared with Example 1, the only difference is that the particle size d90 of the levamlodipine besylate raw material is changed to 18.6 μm, and the rest are the same.
[0201] Comparative Example 21
[0202] Compared with Example 1, the only difference is that the particle size d90 of the levamlodipine besylate raw material is changed to 96 μm, and the rest are the same.
[0203] Effect evaluation
[0204] The valsartan levamlodipine tablets obtained in Examples 1 to 6 and Comparative Examples 1 to 21 were mixed with a marketed control preparation (valsartan tablets: specification: 80 mg, batch number AR7108E, manufacturer: NOVARTIS PHARMACEUTICALS CORP; amlodipine besylate tablets: specification: 5 mg, batch number 8150610, manufacturer: Pfizer Pharmaceuticals Co., Ltd.) in vitro dissolution curves were compared in pH 4.5 acetate buffer. The dissolution results are shown in Table 8 (dissolution results of the finished preparations obtained in Examples 1 to 6 and the control preparation (amlodipine besylate tablets); the dissolution medium is pH 4.5 acetate buffer, 900 mL, 50 rpm, paddle method), Table 9 (dissolution results of the finished preparations obtained in Comparative Examples 1 to 21 and the control preparation (amlodipine besylate tablets); the dissolution medium is pH 4.5 acetate buffer, 900 mL, 50 rpm, paddle method) and Table 10 (dissolution results of the finished preparations obtained in Examples 1 to 6 and Comparative Examples 18 to 21 and the control preparation (valsartan tablets); the dissolution medium is pH 4.5 acetate buffer, 900 mL, 50 rpm, paddle method), and the dissolution curve diagram is shown in Table 11. Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 and Figure 7 .
[0205] Table 8:
[0206]
[0207] Table 9:
[0208]
[0209] Table 10:
[0210]
[0211] Note 1: F2 represents the similarity factor with the control preparation. It is calculated at the time points of 5min, 10min, 15min, 30min, and 45min. If F2 is greater than 50, it indicates that the dissolution conditions are similar in vitro to those of the control preparation. The calculation formula for the F2 value is as follows:
[0212] .
[0213] Wherein, F2 is the similarity factor, n is the number of sampling times, R t is the cumulative dissolution amount (%) of the control preparation sampled at the tth time, T t is the cumulative dissolution amount (%) of the t-th sampling example or comparative example.
[0214] Note 2: The dissolution of amlodipine besylate in Comparative Examples 1 to 17 was significantly different from that of the control preparation, so the dissolution difference of valsartan was not measured.
[0215] From the above experimental results, it can be seen that in Examples 1 to 6, the dissolution of levamlodipine besylate is similar to that of the control preparation, and all are rapid dissolution (more than 85% dissolution in 15 minutes), and the dissolution of valsartan can also fit the control preparation (F2>50), and Example 1 is the best embodiment. In Comparative Examples 1 to 21, except for Comparative Examples 18 and 19 (the valsartan particle size is outside the range), the other comparative examples cannot meet the 15-minute dissolution of more than 85%. Comparative Examples 18 and 19 are valsartan particle sizes outside the preferred range, and the dissolution of the valsartan component cannot fit the control preparation.
[0216] The above results show that the levamlodipine besylate components corresponding to Examples 1 to 6 can achieve the same rapid dissolution as the control preparation, and the valsartan component can also meet the requirements similar to the control preparation, while the levamlodipine besylate components and the valsartan components in Comparative Examples 1 to 21 cannot simultaneously meet the requirements that the 15min dissolution rate of amlodipine besylate is greater than 85% and the F2 value of valsartan is greater than 50. It can be seen that the prior art cannot achieve the beneficial effects that can be achieved by the present invention, and the beneficial effects achieved by the present invention are not obtained by arbitrarily selecting the particle size d90 of the raw material, the type of the coating agent, the ratio of levamlodipine besylate to the coating agent, and the coating process.
[0217] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A valsartan-amlodipine tablet composition, characterized in that: It is composed of a valsartan composition and a levamlodipine besylate composition; The valsartan composition is composed of valsartan, a filler, a disintegrant, a glidant and a lubricant 1; The levoamlodipine besylate composition is composed of levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2; The particle size d90 of the valsartan is 10-100 μm, and the particle size d90 of the levamlodipine besylate is 20-90 μm; In the levoamlodipine besylate composition, the mass ratio of the levoamlodipine besylate to the sodium carboxymethyl starch is 7:9-14; The lubricant 1 is selected from at least one of magnesium stearate and calcium stearate; The lubricant 2 is selected from at least one of magnesium stearate and calcium stearate; The preparation method of the valsartan levamlodipine tablets comprises the following steps: S1, mixing the prescribed amount of the valsartan composition, and dry granulating to obtain valsartan granules; S2, mixing the sodium carboxymethyl starch and levoamlodipine besylate in the prescription amount of the levoamlodipine besylate composition for 1-5 min, adding 45%-55% by weight of the valsartan granules obtained in step S1, mixing for 8-10 min, and then adding the remaining weight of the valsartan granules obtained in step S1, mixing for 8-10 min, to obtain coated granules; S3, mixing the coated particles obtained in step S2 with the lubricant 2 in the prescribed amount of the levamlodipine besylate composition, and tableting to obtain tablet cores; S4, coating the tablet cores obtained in step S3 to obtain valsartan levamlodipine tablets.
2. The valsartan levamlodipine tablet composition according to claim 1, characterized in that: In the valsartan composition, the filler is selected from at least one of microcrystalline cellulose and pregelatinized starch, the disintegrant is selected from at least one of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone, the glidant is colloidal silicon dioxide, and the lubricant 1 is magnesium stearate; In the levamlodipine besylate composition, the lubricant 2 is magnesium stearate.
3. The valsartan levamlodipine tablet composition according to claim 1, characterized in that: In the valsartan composition, the mass ratio of the valsartan, the filler, the disintegrant, the glidant and the lubricant 1 is 80:50-75:8-22:1.3-3:0.5-3.
4. The valsartan levamlodipine tablet composition according to claim 1, characterized in that: In the levoamlodipine besylate composition, the mass ratio of the levoamlodipine besylate, sodium carboxymethyl starch and lubricant 2 is 7:9-14:1-2.
4.
5. The valsartan levamlodipine tablet composition according to claim 1, characterized in that: The filler is microcrystalline cellulose 102, the disintegrant is cross-linked polyvinylpyrrolidone XL, the glidant is colloidal silicon dioxide, the lubricant 1 is magnesium stearate, and the lubricant 2 is magnesium stearate; The mass ratio of valsartan, filler, disintegrant, glidant, lubricant 1, levamlodipine besylate, sodium carboxymethyl starch and lubricant 2 is 80:55:22:1.3:3:3.5:7:1.2; The particle size d90 of the valsartan is 11.8 μm, and the particle size d90 of the levamlodipine besylate is 89.5 μm.
6. The valsartan levamlodipine tablet composition according to claim 1, characterized in that: In the valsartan composition, the mass percentage of valsartan in the valsartan levoamlodipine tablet composition is 42.78%-48.34%, the mass percentage of the filler in the valsartan levoamlodipine tablet composition is 30.21%-40.11%, the mass percentage of the disintegrant in the valsartan levoamlodipine tablet composition is 4.57%-12.72%, the mass percentage of the glidant in the valsartan levoamlodipine tablet composition is 0.73%-1.81%, and the mass percentage of the lubricant 1 in the valsartan levoamlodipine tablet composition is 0.27%-1.73%; In the levoamlodipine besylate composition, the mass percentage of the levoamlodipine besylate in the valsartan levoamlodipine tablet composition is 1.96%-4.23%, the mass percentage of the sodium carboxymethyl starch in the valsartan levoamlodipine tablet composition is 2.79%-8.46%, and the mass percentage of the lubricant 2 in the valsartan levoamlodipine tablet composition is 0.60%-0.86%.
7. The valsartan levamlodipine tablet composition according to claim 6, characterized in that: In the valsartan composition, the mass percentage of valsartan in the valsartan levoamlodipine tablet composition is 46.24%, the mass percentage of the filler in the valsartan levoamlodipine tablet composition is 31.79%, the mass percentage of the disintegrant in the valsartan levoamlodipine tablet composition is 12.72%, the mass percentage of the glidant in the valsartan levoamlodipine tablet composition is 0.75%, and the mass percentage of the lubricant 1 in the valsartan levoamlodipine tablet composition is 1.73%; In the levoamlodipine besylate composition, the mass percentage of the levoamlodipine besylate in the valsartan levoamlodipine tablet composition is 2.02%, the mass percentage of the sodium carboxymethyl starch in the valsartan levoamlodipine tablet composition is 4.05%, and the mass percentage of the lubricant 2 in the valsartan levoamlodipine tablet composition is 0.69%.
8. A valsartan levamlodipine tablet, characterized in that: The invention comprises a tablet core and a coating layer, wherein the tablet core is made of the valsartan levoamlodipine tablet composition according to any one of claims 1 to 7.
9. The valsartan levamlodipine tablets according to claim 8, characterized in that: The mass of the coating layer is 2.5%-5.5% of the mass of the tablet core; the coating layer is prepared from a gastric soluble film coating premix.
10. The valsartan levoamlodipine tablets according to claim 9, characterized in that: The mass of the coating layer is 4.5% of the mass of the tablet core; The coating layer is prepared from a gastric soluble film coating premix water suspension with a mass concentration of 10%-15%.
11. The process for preparing the valsartan levamlodipine tablets according to any one of claims 8 to 10, characterized in that: The following steps are involved: S1, mixing the prescribed amount of the valsartan composition, and dry granulating to obtain valsartan granules; S2, mixing the sodium carboxymethyl starch and levoamlodipine besylate in the prescription amount of the levoamlodipine besylate composition for 1-5 min, adding 45%-55% by weight of the valsartan granules obtained in step S1, mixing for 8-10 min, and then adding the remaining weight of the valsartan granules obtained in step S1, mixing for 8-10 min, to obtain coated granules; S3, mixing the coated particles obtained in step S2 with the lubricant 2 in the prescribed amount of the levamlodipine besylate composition, and tableting to obtain tablet cores; S4, coating the tablet cores obtained in step S3 to obtain valsartan levamlodipine tablets.
12. The preparation process according to claim 11, characterized in that: In step S1, the dry granulation is specifically carried out using a dry granulator, with a feed speed of 25-80 rpm, a roller speed of 5-20 rpm, an oil pump pressure of 30-70 bar, a roller gap of 0.4-1.0 mm, a crushing speed of 80-100 rpm, a granulation speed of 80-100 rpm, and a granulation screen aperture of 0.8 mm.
13. The preparation process according to claim 11, characterized in that: In step S2: The sodium carboxymethyl starch and levoamlodipine besylate in the prescribed amount of the levoamlodipine besylate composition were mixed for 3 minutes.
14. The preparation process according to claim 11, characterized in that: In step S2: 50% of the mass of the valsartan granules obtained in step S1 are added, mixed for 8-10 minutes, and then the remaining mass of the valsartan granules obtained in step S1 are added, mixed for 8-10 minutes to obtain coated granules.
15. The preparation process according to claim 14, characterized in that: In step S2: 50% of the mass of the valsartan granules obtained in step S1 were added, mixed for 10 minutes, and then the remaining mass of the valsartan granules obtained in step S1 were added, mixed for 8 minutes to obtain coated granules.
16. The preparation process according to claim 11, characterized in that: The mixing time in step S3 is 3-7 minutes; in step S3, the average hardness of the tablet is 50-90N.
17. The preparation process according to claim 16, characterized in that: The mixing time in step S3 is 3 minutes; in step S3, the average hardness of the tablet is 85N.
18. The preparation process according to claim 11, characterized in that: In step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a suspension aqueous solution with a mass concentration of 10%-15% for coating, so that the mass of the coating accounts for 2.5%-5.5% of the mass of the tablet core obtained in step S3.
19. The preparation process according to claim 18, characterized in that: In step S4, the coating is specifically performed by using a gastric soluble coating premix to prepare a suspension aqueous solution with a concentration of 15% by mass, so that the coating mass accounts for 4.5% of the mass of the tablet core obtained in step S3.
20. Use of the preparation process according to any one of claims 11 to 19 in drug production.
